These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31387898)

  • 1. Immunosuppressive Immature Myeloid Cell Generation Is Controlled by Glutamine Metabolism in Human Cancer.
    Wu WC; Sun HW; Chen J; OuYang HY; Yu XJ; Chen HT; Shuang ZY; Shi M; Wang Z; Zheng L
    Cancer Immunol Res; 2019 Oct; 7(10):1605-1618. PubMed ID: 31387898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice.
    Forghani P; Harris W; Giver CR; Mirshafiey A; Galipeau J; Waller EK
    PLoS One; 2013; 8(7):e64837. PubMed ID: 23843936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamine Deprivation Promotes the Generation and Mobilization of MDSCs by Enhancing Expression of G-CSF and GM-CSF.
    Sun HW; Wu WC; Chen HT; Xu YT; Yang YY; Chen J; Yu XJ; Wang Z; Shuang ZY; Zheng L
    Front Immunol; 2020; 11():616367. PubMed ID: 33603745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
    Sumida K; Wakita D; Narita Y; Masuko K; Terada S; Watanabe K; Satoh T; Kitamura H; Nishimura T
    Eur J Immunol; 2012 Aug; 42(8):2060-72. PubMed ID: 22653638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
    Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
    Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    J Immunol; 2012 Jun; 188(12):6389-98. PubMed ID: 22586039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-programmed nutrient partitioning in the tumour microenvironment.
    Reinfeld BI; Madden MZ; Wolf MM; Chytil A; Bader JE; Patterson AR; Sugiura A; Cohen AS; Ali A; Do BT; Muir A; Lewis CA; Hongo RA; Young KL; Brown RE; Todd VM; Huffstater T; Abraham A; O'Neil RT; Wilson MH; Xin F; Tantawy MN; Merryman WD; Johnson RW; Williams CS; Mason EF; Mason FM; Beckermann KE; Vander Heiden MG; Manning HC; Rathmell JC; Rathmell WK
    Nature; 2021 May; 593(7858):282-288. PubMed ID: 33828302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.
    Kohanbash G; McKaveney K; Sakaki M; Ueda R; Mintz AH; Amankulor N; Fujita M; Ohlfest JR; Okada H
    Cancer Res; 2013 Nov; 73(21):6413-23. PubMed ID: 24030977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity.
    Byun JK; Park M; Lee S; Yun JW; Lee J; Kim JS; Cho SJ; Jeon HJ; Lee IK; Choi YK; Park KG
    Mol Cell; 2020 Nov; 80(4):592-606.e8. PubMed ID: 33159855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models.
    Hammami I; Chen J; Murschel F; Bronte V; De Crescenzo G; Jolicoeur M
    BMC Cell Biol; 2012 Jul; 13():18. PubMed ID: 22762146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer modulates the immunosuppressive function of CD11b
    Udumula MP; Sakr S; Dar S; Alvero AB; Ali-Fehmi R; Abdulfatah E; Li J; Jiang J; Tang A; Buekers T; Morris R; Munkarah A; Giri S; Rattan R
    Mol Metab; 2021 Nov; 53():101272. PubMed ID: 34144215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.
    Park YJ; Song B; Kim YS; Kim EK; Lee JM; Lee GE; Kim JO; Kim YJ; Chang WS; Kang CY
    Cancer Res; 2013 Sep; 73(18):5669-81. PubMed ID: 23867469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
    Kusmartsev S; Nefedova Y; Yoder D; Gabrilovich DI
    J Immunol; 2004 Jan; 172(2):989-99. PubMed ID: 14707072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PD-L1-targeting Regulator for Metabolic Reprogramming to Enhance Glutamine Inhibition-Mediated Synergistic Antitumor Metabolic and Immune Therapy.
    Jin XK; Zhang SM; Liang JL; Zhang SK; Qin YT; Huang QX; Liu CJ; Zhang XZ
    Adv Mater; 2024 Feb; 36(6):e2309094. PubMed ID: 38014890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
    Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
    Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.